Clinical Trial Update: Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of pemetrexed plus bevacizumab for recurrent ovarian cancer and primary peritoneal cancer has completed; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Avastin (bevacizumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Ovarian Carcinoma, Primary Peritoneal Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-10-20